Publikationen
Prof. Dr. Bernd Joachim Krause
Prof. B. J. Krause
Originalarbeiten in wissenschaftlichen Fachzeitschriften 2011-2018
Stand: August 2018
2018
Nuklearmedizin in Deutschland
Krause BJ
Nuklearmedizin 2018;57(3):66-67
Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements
Roolf C, Richter A, Konkolefski C, Knuebel G, Sekora A, Krohn S, Stenzel J, Krause BJ, Vollmar B, Murua Escobar H, Lunghanns C
J Hematol Oncol 2018;11:62
External radiation exposure, excretion, and effective half-live in 177Lu-PSMA-targeted therapies
Kurth J, Krause BJ, Schwarzenböck SM, Stegger L, Schäfers M, Rahbar K
EJNMMI Res. 2018;8:32
Somatostatin receptor PET/CT (SSTR-PET/CT)
Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A
Nuklearmedizin 2018;57(1):4-17
[18F]fallypride-PET/CT Analysis of the Dopamine D₂/D₃ Receptor in the Hemiparkinsonian Rat Brain Following Intrastriatal Botulinum Neurotoxin A Injection.
Mann T, Kurth J, Hawlitschka A, Stenzel J, Lindner T, Polei S, Hohn, A, Krause BJ, Wree A
Molecules 2018;23(3):587
Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity and the effect of hematological toxticity on survival
Löser A, Schwarzenböck SM, Heuschkel M, Willenberg HS, Krause BJ, Kurth J
Nucl Med Commun 2018;39(3):236-246
Antifibrogenic effects of vitamin D derivatives on mouse pancreatic stellate cells
Wallbaum P, Rohde S, Lange F, Hohn A, Bergner C, Schwarzenböck SM, Krause BJ, Jaster R
World J Gastroenterol 2018;24(2):170-178
[18F] FDG PET/CT for assessing inguinal Lymph nodes in patients with penile cancer –correlation with histopathology after inguinal lymphadenectomy
Dräger DL, Heuschkel M, Protzel Ch, Erbersdobler, Krause BJ, Hakenberg OW, Schwarzenböck SM
Nuklearmedizin 2018;57(1):26-30
EANM/EARL FDG-PET/CT accreditation – summery results from the first 200 accredited imaging systems
Kaalep A, Sera T, Oyen W, Krause BJ, Chiti A, Liu Y. Boellaard R
Eur J Nucl med Mol Imaging 2017;45(3):412-422
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delcado Bolton RC, Gabriel M
Eur J Nucl med Mol Imaging 2018;45(5):824-845
2017
Iterative Learning Control of a Pneumatically Actuated Lung Tumour Mimic Mode
Wache A, Aschemann H, Prabel R, Kurth J, Krause BJ, Zorn S
IFAC-PapersOnLine 2017;50(1):7592-7597
Nonlinear Tracking Control of a Pneumatically Actuated Lung Tumour Mimic Model
Prabel R, Aschemann H, Kersten J, Schuenemann P, Kurth J, Krause BJ, Jonuchies I
IFAC-PapersOnLine 2016;49:71-76
[68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression
Schwarzenböck SM, Stenzel J, Otto T, Helldorff HV; Bergner C, Kurth J, Polei S, Lindner T, Rauer R, Hohn A, Hakenberg OW, Wester HJ, Bollmar B, Krause BJ
Oncotarget 2017;8(56):95606-95619
APPswe/PS1dE9 mice with cortical amyloid pathology show a reduced NAA/Cr ratio without apparent brain atrophy: A MRS and MRI stady
Kuhla A, Rühlmann C, Lindner T, Polei S, Hadlich S, Krause BJ, Vollmar B, Teipel SJ
Neuroimage Clin 2017:15;581-586
Application of in vivo techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer
Rohde S, Lindner T, Polei S, Stenzel J, Borufka L, Achilles S, Hartmann E, Lange F, Maletzki C, Linnebacher M, Glass Ä, Schwarzenböck SM, Kurth J, Hohn A, Vollmar B, Krause BJ, Jaster R
Oncotarget 2017;8(41):69756-69767
Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin
Schmid SC, Sathe A, Guerth F, Seitz AK, Heck MM, Maurer T, Schwarzenböck S, Krause BJ, Schulz WA, Stoehr R, Gschwend JE, Retz M, Nawroth R
Urologic Oncology 2017;35(9):544.e1-544.e10
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions
Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny Ch, Hofmann MS, Eiber M, Schwarzenböck S, Castellucci P, Bellisario C, Chauvie St, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A
Eur J Nucl med Mol Imaging 2017;44(10):1622-1635
Cardiac cell therapies fort he treatment of acute myocardial infarction: A meta-analysis from mouse studies
Lang CI, Wolfien M, Langenbach A, Müller P, Wolkenhauer O, Yavari A, Ince H, Steinhoff G, Krause BJ, David R, Glass Ä
Cell Physiol Biochem 2017;42:254-268
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guidline for prostate cancer imaging: version 1.0
Fendler WP, Eiber M, Behesthi M, Bomanji J, Ceci F, Cho St, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti St, Herrmann K
Eur J Nucl Med Mol Imaging 2017;44:1014-1024
Monitoring cytotoxicity of gemcitabine and cisplatin in T24 bladder cancer cells by the use of F-18-FDG and F-18-FMC
Rabenstein J, Fischer DC, Hakenberg OW, Jahn D, Rutz W, Hohn A, Heuschkel M, Cuber Ch, Krause BJ
Int J Clin Exp Med 2017;10(3):4556-4564
German multicenter study investigating 177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
Rahbar K, Ahmadzadehfar C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarani HR, Schmidt M, Bartenstein P, Pfestroff A, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann, M, Fendler WP, Krause BJ
J Nucl Med 2017;58:85-90
[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy
Schwarzenböck SM, Knieling A, Souvatzoglou M, Kurth J, Steiger K, Eiber M, Esposito I, Retz M, Kübler H, Gschwend JE, Schwaiger M, Krause BJ, Thalgott M
Oncotarget 2017;7(39):63747-63757
2016
Evaluation of prostate cancer with 11C- and 18F-Choline PET/CT: Diagnosis and initial staging
Nitsch S, Hakenberg OW, Heuschkel M, Dräger D, Hildebrandt G, Krause BJ, Schwarzenböck SM
J Nucl Med 2016;57(Suppl 3):38S-42S
Radionuklidtherapie von Knochenmetastasen mittels Radium-223; S1 Leitlinie
Pöppel, TD, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Mitterhauser M, Scheidhauer K, Schenck M, Sonnenschein W, Gabriel M
Nuklearmedizin 2016;55(5):177-186
Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate Cancer
Schwarzenböck SM, Eiber M, Kundt G, Retz M, Sakretz M, Kurth J, Treiber U, Nawroth R, Rummeny EJ, Gschwend JE, Schwaiger M, Thalgott M, Krause BJ
Eur J Nucl Med Mol Imaging 2016;43(12):2105-2113
The 2015 Revised American Thyreoid Association guidlines for the management of medullary thyreoid carcinoma: the „evidence-based“ refusal to endorse them by EANM due to „not evidence-based“ marginalization oft he role of Nuclear Medicine
Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ, Langsteger W, Verburg FA, Luster M
Eur J Nucl Med Mol Imaging 2016;43:1486-1490
Beta-Amyloid-PET-Bildgebung des Gehirns
Barthel H, Meyer PT, Drzezga A, Bartenstein P, Boecker H, Brust P, Buchert R, Coenen HH, la Fougére C, Gründer G, Grünwald F, Krause BJ, Kuwert T, Schreckenberger M, Tatsch K, Langen K-J, Sabri O
Nuklearmedizin 2016;55(4):129-137
Therapie mit 177Lu-PSMA-617 – Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom
Fendler WP, Kratochwill C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heizel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ
Nuklearmedizin 2016;55(3):123-128
Increased choline uptake in macrophages and prostate cancer cells does not allow for differentiation between benign and malignant prostate pathologies
Schwarz T, Seidl C, Schiemann M, Senekowitsch-Schmidtke R, Krause BJ
Nuclear Medicine and Biology 2016;43:355-359
Non-invasive assessment of inter- and intrapatient variability of integrin expression in metastasized prostate cancer by PET
Beer AJ, Schwarzenböck S, Zantl N, Sovatzoglou M, Maurer T, Watzlowik P, Kessler H, Wester HJ, Schwaiger M, Krause BJ
Oncotarget 2016;7(19)28151-28159
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasm in Germany: A multi-institutional registry study with prospective follow-up
Hörsch D, Ezzidin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, Schreckenberger M, Krause BJ, Bengel FM, Bartenstein P, Biersack HJ, Pöpperl G, Baum RP
Eur J Cancer 2016;58:41-51
18F-fluoroethyl-l-thyrosine (FET) PET to delineate tumor residuals after glioblastoma resection: A comparison to standard postoperative MRI
Buchmann N, Kläsner B, Gempt J, Bauer JS, Pyka T, Delbridge C, Meyer B, Krause BJ, Ringel F
World Neurosurg. 2016;89:420-426
Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer
Verburg FA, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ, Langsteger W, Luster M; EANM and the EANM Thyroid Committee.
Eur J Nucl Med Mol Imaging 2016;43(6):1001-1005
PET/CT with 11 C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta analysis and critical review of available data
Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ, Oyen W, Chiti A
Eur J Nucl Med Mol Imaging 2016;43:55-69
CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1
Sathe A, Koshy N, Schmid SC, Thalgott M, Schwarzenböck SM, Krause BJ, Holm PS, Gschwend JE, Retz M, Nawroth R
J Urol 2016;195:771-779
Cardiac FDG-PET: a straight forward tool with high potential
Lang CI, Krause BJ, David R
Eur Heart J Cardiovasc Imaging 2016;17:130-131
Comparison of [11C]Choline ([ 11C]CHO) and [18F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model
Schwarzenböck SM, Schmeja P, Kurth J, Souvatzoglou M, Nawroth R, Treiber U, Kundt G, Berndt S, Graham K, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Dinkelborg L, Wester HJ, Krause BJ
Mol Imaging Biol 2016;18(3):393-401
2015
Die Cholin PET/CT für Diagnostik, Staging und Restaging des Prostatakarzinoms
Heuschkel M, Krause BJ, Hakenberg OW, Schwarzenböck SM
Der Nuklearmediziner 2015:38(2):109-118
The relative importance of imaging markers fort he prediction of Alzheimer´s disease in mild cognitive impairmend – Beyond classical regression
Teipel SJ, Kurth J, Krause BJ, Grothe MJ
Neuroimage Clin 2015;8:583-593
18F-NaF PET/CT: EANM procedure guidlines for bone imaging
Beheshti M, Mottaghy FM, Payche F, Behrendt FFF, Van den Wyngaert T, Fogelmann I, Strobel K, Celli M, Fanti S, Giammarile F, Krause BJ, Langsteger W
Eur J Nucl Med Mol Imaging 2015:42;1767-1777
Early [18F]FET-PET in Gliomas after surgical resection: Comparison with MRI and histopathologie
Kläsner B, Buchmann N, Gempt J, Ringel F, Lapa C, Krause BJ
PLOS one 2015:26;10(10):e0141153
124I-PET Assessment of human sodium iodide symporter reporter gene activity for highly sensitive in vivo monitoring of teratoma formation in mice
Lehner S, Lang C, Kaissis G, Todica A, Zacher MJ, Boening G, Spitzweg C, Herbach N, Franz WM, Krause BJ, Steinhoff G, Bartenstein P, Hacker M, David R
Mol Imaging Biol 2015;17(6):874-883
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
Thalgott M, Rack B, Eiber M, Souvatzoglou M, Heck MM, Kronester C, Andergassen U, Kehl V, Krause BJ, Gschwend JE, Retz M, Nawroth R
BMC Cancer 2015;15:458
Wie schreibe ich eine gute Übersichtsarbeit?
Krause BJ, Khan C, Antoch G
Nuklearmedizin 2015;54(2):69-74
Robust, fully automatic delineation of the head contout by sterotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy
Lange C, Kurth J, Seese A, Schwarzenböck S, Steinhoff K, Umland-Seidler B, Krause BJ,
Brenner W, Sabri O, Hesse S, Buchert R
Eur Rad 2015 ;25:2709-2717
Circulating tumor cells versus objective response assessment predicting survival in metastastic castration-resistant prostate cancer patients treated with docetaxel chemotherapy
Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M, Gschwend JE, Andergassen U, Nawroth R
J Cancer Res Clin Oncol 2015;141(8):1457-1464
Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor-exprimierender Tumore
DGN Leitlinie (S1)
Poeppel TD, Boy C, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Krause BJ, Schmidt D, Amthauer H, Rösch F, Nagarajah, Führer D, Lahner H, Pöpperl G, Hörsch D, Walter MA, Baum RP
Nuklearmedizin 2015;54(1):1-11
Positronenemissionstomographie 2013 in Deutschland
Kotzerke J, Oehme L, Grosse J, Hellwig D, Arbeitsausschuss PET der DGN u. a. Krause BJ
Nuklearmedizin 2015;54(2):53-59
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ.
Eur J Nucl Med Mol Imaging 2015;42(2):328-354
Comparison of [11C]Choline ([ 11C]CHO) and S(+)-β-Methyl-[11C]Choline ([ 11C]SMC) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model
Schwarzenböck SM, Gertz J, Souvatzoglou M, Kurth J, Sachs D, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester HJ, Krause BJ
Mol Imaging Biol 2015;17(2):248-256
Prediction of Parkinson´s disease subsequent to severe depression: a ten-year follow-up study
Walter U, Heilmann R, Kaulitz L, Just T, Krause BJ, Benecke R, Höppner J
J neural Transm 2015;122(6):789-797
Repetitive transcranial magnetic stimulation (rTMS) in schizophrenia with treatment-refractoty auditory hallucinations and major self-mutilation
Schulz T, Berger Ch, Krecklow B, Kurt J, Schwarzenboeck S, Foley P, Thome J, Krause BJ, Hoeppner J
J Neural Transm 2015;122(S1): 19-23
2014
Alzheimer – Frühere Diagnostik dank neuer Bildgebungstechniken
Kurth J, Kasper E, Teipel S, Krause BJ
DZKF 2014;14-19
CT-based attenuation correction in I-123-Ioflupane SPECT
Lange C, Seese A, Schwarzenböck S, Steinhoff K, Umland-Seidler B, Krause BJ, Brenner W, Sabri O, Kurth J, Hesse S, Buchert R
PLOS one 2014;9(9):e108238
Welche bildgebenden Verfahren sind in der Demenz-Diagnostik sinnvoll?
Sakretz M, Kurth J, Teipel S, Krause BJ
DNP-Der Neurologe&Psychiater 2014;15(10)
11C-Choline PET/ pathology image coregistration in primary localized prostate cancer
Grosu AL, Weirich G, Wendl C, Prokic V, Kirste S, Geinitz H, Souvatzoglou M, Gschwend JE, Schwaiger M, Molls M, Weber WA, Treiber U, Krause BJ
Eur J Nucl Med Mol Imaging 2014;41(12):2242-2248
In-vivo of the acute retention of stem cell derivatives and fribroblasts after intramyocardial transplantation
Lang, C, Lehner S, Todica A, Boening G, Zachert M, Franz WM, Krause BJ, Bartenstein P,
Hacker M, David R
Eur J Nucl Med Mol Imaging 2014;41(12):2325-2336
Ösophagus- und Magenkarzinom – Staging und Bildgebung
Schwarzenböck S, Krause BJ, Ebert M, Grenacher L
Klinikarzt 2014;43:348-353
Prognostic Value of 11C-Choline PET/CT and CT for Predicting Survival of Bladder
Cancer Patients Treated with Radical Cytectomy
Mauerer T, Horn T, Souvatzoglou M, Eiber M, Beer AJ, Heck MM, Haller B, Gschwend JE,
Schwaiger M, Treiber U, Krause BJ
Urol Int 2014;93(2):207-213
Preoperative lymph node Staging in patients with primary prostate cancer: Comparison and correlation of quantitative imaging parameters in diffusion weighted imaging [11C]-choline PET/CT
Vag T, Heck M, Beer AJ, Souvatzoglou M, Weirich G, Holzapfel K, Krause BJ, Schwaiger M, Eiber M
Eur Radiol 2014;24(8):1821-1826
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells
Elsner A, Lange F, Fitzner B, Heuschkel M, Krause BJ, Jaster R
World J of Gastro2014;20(24):7914-7925
Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C] choline positron emission tomography/ computed tomography for preoperative lymph node staging in prostate cancer patients
Heck M, Souvatzoglou M, Retz M, Nawroth R, Kübler H, Maurer T, Thalgott M, Gramer BM, Weirich G, Rondak IC, Rummeny EJ, Schwaiger M, Gschwend JE, Krause BJ, Eiber M
Eur J Med Mol Imaging 2014;41:694-701
Cholinergic basal forebrain atrophy predicts amyloidburden in Alzheimer`s disease
Teipel S, Heinsen H, Amaro Jr. E, Grinberg LT, Krause BJ, Grothe M, fort he Alzheimer`s Disease Neuroimaging Initiative
Neurobiology of Aging 2014;35:482-491
European Association of Nuclear medicine: adapt the present, shape the future
Frangos S, Knapp W, - on behalf of the EANM Executive Committee (Krause BJ)
Eur J Nucl Med Mol Imaging 2014;41:590-591
Quality criteria for multidisciplinary oncology guidelines – the ECCO multidisciplinary clinical guidlines forum
Schrijvers D, van den Velde C, Bregni M, Caraceni A, Cardoso F, Erdem S, Geldenborn H, Grisold W, Honore PGH, Krause BJ, Licitra L, Mansel R, Margilies H, Parsons K, Poston G, Valentini V, Zola P
Eur Assoc Neurooncol Mag 2014;4(1):6-8
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
Thalgott M, Horn T, Heck M, Maurer T, Eiber M, Retz M, Autenrieth M, Herkommer K, Krause BJ, Gschwend JE, Treiber U, Kübler HR
J of Hema & Oncol 2014;7:20
Molekulare multimodale Hybridbildgebung des Prostata- und Blasenkarzinoms
Maurer T, Eiber M, Krause BJ
Der Urologe 2014;53:469-483
Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects
Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ, für the Alzheimer´s Disease Neuroimaging Initiative
Alzheimer`s & Dementia 2014:10:S344-S353
2013
Perfusion brain imaging with SPECT-technique. German Guidline S1
Kranert T, Menzel C, Bartenstein P, Brust P, Coenen HH, Krause BJ, Kuwert T, Sabri O, Schreckenberger M, Tatch K, Grünwald F
Nuklearmedizin 2013;52(5):157-162
Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates
Krause BJ, Souvatzoglou M, Treiber U.
Urol Oncol 2013 May;31(4):427-435
Smolarz K, Krause BJ, Graner FP, Wagner FM, Wester HJ, Sell T, Bacher-Stier C, Fels L, Dinkelborg L, Schwaiger M.
Eur J Nucl Med Mol Imaging 2013;40(12):1861-1868
Schwarzenböck S, Sachs D, Souvatzoglou M, Schuster T, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler S, Schwaiger M, Senekowitsch-Schmidtke R, Krause BJ.
Nuklearmedizin 2013 Aug 8;52(4):141-147
Molecular imaging of dementia
Kurth J, Sakretz M, Teipel S, Krause BJ
Geriatric Mental Health Care 2013;1(3):56-62
Das Peniskarzinom
Protzel C, Kakies C, Schwarzenböck S, Kuhnt T, Ebersdobler A, Krause BJ, Hakenberg OW
Der Onkologe 2013;19(2):149-162
Molecular imaging techniques in the diagnosis of dementia
Kurt J, Kilimann I, Krause BJ, Teipel S
Nervenheilkunde2013;32:725-732
Tumour volume delineation in prostate cancer assessed by (11C)choline PET/C/: validation with surgical specimens
Bundschuh RA, Wendl CM, Weirich G, Eiber M, Sovatzoglou M, Treiber U, Küberler H, Maurer T, Gschwend JE, Geinitz H, Grosu AL, Ziegler SI, Krause BJ
Eur J Nucl Med Mol Imaging 2013;40(6):824-831
Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer
Schwarzenböck S, Kurth J, Gocke C, Kuhnt T, Hildebrandt G, Krause BJ
Eur J Nucl Med Mol Imaging 2013;40(Suppl 1):28-35
(S)-4-(3-18F-Fluoropropyl)-L-Glutamic Acid: An 18F-Labaled Tumor-Specific Probe for PET/CT Imaging-Dosimetry
Smolarz K, Krause BJ, Graner FP, Wagner FM, Hultsch C, Bacher-Stier C, Sparka RB, Ramsay S, Fels LM, Nunkelborg LM, Schwaiger M
J Nucl Med 2013;54(6):861-866
2012
S3-guidline-diagnosis and treatment of gastric carcinoma:relevance for radiologic imaging
Grenacher L, Schwarz M, Lordick F, Krause BJ, Roecken C, Moening S, Ebert M, Jenssen C, Kauczor HU, Moehler M, Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
Rofo 2012;184(8):706-12
PET/CT and choline: diagnosis and staging
Farsad M, Schwarzenböck S, Krause BJ
Q J Nucl Med Mol Imaging 2012;56(4):343-353
SNM/EANM Guidline for Guideline Development 6.0
Delbeke D, Chiti A, Christian P, Darcourt J, Donohoe K, Flotats, Krause BJ, Royal HD,
J Nucl Med Technol 2012;40:283-289
18F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions
Buck D, Förschler A, Lapa C, Schuster T, Vollmar P, Korn T, Nessler S, Stadelmann C, Drzezga A, Buck AK, Wester HJ, Zimmer C, Hemmer B, Krause BJ
J Nucl Med 2012;53(8):1269-1276
Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy
Maurer T, Souvatzoglou M, Kübler H, Opercan K, Schmidt S, Herrmann K, Stollfuss J, Weirich G, Haller B, Gschwend JE, Schwaiger M, Krause BJ, Treiber U
Eur Urol 2012;61(5):1031-1038
Choline PET and PET/CT in primary diagnosis and staging of prostate cancer
Schwarzenböck S, Souvatzoglou M, Krause BJ
Theranostics 2012;2(3):318-330
Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients with Lymph Node Metastases
Fortuin AS, Daserno WMLLG, Meijer HJM, Jager GJ, Takahashi S, Debats OA, Reske SN, Schick C, Krause BJ, van Oort I, Witjes AJ, Hoogeveen YL, van Lin ENJ, Baretsz JO
Int J Radiation Oncol Biol Phys 2012;84(3):712-718
2011
Letter to the Editor: Re: Mottet N, Bellmunt J, Bolla M, et all: EAU Guidelines on prostate Cancer Part II: Treatment of advanced, relapsing and gastration-resistant prostate Caner
Eur Urol 2011;60:e37-e38
PET/CT for the diagnosis, staging and restaging of prostate cancer
Souvatzoglou M, Gärtner F, Schwarzenböck S, Beer AJ, Schwaiger M, Krause BJ
Imaging in Medicine 2011;3(5):571-585
Welche neuen PET-Tracer braucht die Strahlentherapie?
Schwarzenböck S, Herrmann K, Gärtner F, Kläsner B, Souvatzoglou M, Krause BJ
Der Nuklearmediziner 2011;34(2);99-108
18F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can do
Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czemin J.
Q J Nucl Med Mol Imaging 2011;55(6):620-632
S6K1 and 4E-BP1 are independent regulated and control cellular growth in Bladder cancer
Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE, Retz M
PLoS One 2011;6(11):e27509
Prognistic value of (18F)-Flurop-Deoxy-Glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma
Essler M, Link A, Belloni B, Mirceva V, Souvatzoglou M, Thaler M, Haller B, Hein R, Krause BJ
PloS One 2011;6(9):e24632
Curative treatment of oesophageal carcinoma: current options and future developments
Wolf MC, Stahl M, Krause BJ, Bonavina C, Bruns C, Belka C, Zehentmayr F
Radiat Oncol 2011;6:55
Molecular imaging of proliferation and glucose utilization: utility for monotoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer
Ott K, Hermann K, Schuster T, Lange R, Becker K, Wieder HA, Wester HJ, Siewert JR, Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Pechel C, Schwaiger M, Lordick F, Krause BJ
Ann Surg Oncol 2011;18(12):3316-3323
Positron emission tomography – current role in the diagnostic and treatment of upper gastrointestinal carcinomas
Lordick F, Ott K, Krause BJ
Dtsch. Med. Wochenschr 2011;136(20):1061-1066
German S3-guidline "Diagnosis and treatment of esophagogastric cancer"
Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C; AWMF; AWMF.
Z Gastroenterol. 2011;49(4):461-531
The sensitivity of (11)Choline PET/CT to localize prostate cancer depends on the tumor configuration
Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, Eiber M, Herrmann K, Kuebler H, Wester HJ, Hoefler H, Gschwend J, Schwaiger M, Treiber U, Krause BJ
Clin Cancer Res 2011;17(11):3751-3759
Infuence of (11)Choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochjemical recurrence of prostate cancer
Souvatzoglou M, Krause BJ, Pürschel A, Thamm R, Schuster T, Buck AK, Zimmermann F, Molis M, Schwaiger M, Geinitz H
Radiother Onco 2011;99(2):193-200
18F-FDG-PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the municon II trial
Meyer zum Büschenfelde C, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ
J Nucl Med 2011;52(8):1189-1196
German Guidelines for brain-tumor imaging by PET and SPECT using labeled amino acids
Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A, Grünwald F, Krause BJ, Kuwert T, Sabri O, Tatsch K, Weber WA, Schreckenberger M
Nuklearmedizin 2011;50(4):167-173
Radionuclide and Hybrid Imaging of Recurrent Prostate Cancer
Beer A, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ
Lancet Oncology 2011;12(2):181-191
The Role of choline positron emission tomography/computed tomography in the management of patients with prostatate-specific antigen progression after radical treatment of prostate cancer
Picchio M, Briganti A ,Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN
Eur Urology 2011;59(1):51-60
Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11C-Choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer
Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, Maurer T, Kübler H, Wester HJ, Gaa J, Krause BJ
Mol Imag Biol 2011;13(2):352-361
Comparison of different SUV-based methods for prediction of response to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI
Herrmann K, Bundschuh RA, Rosenberg R, Schmidt S, Praus C, Souvatzoglou M, Becker K, Schuster T, Essler M, Wieder HA, Friess H, Ziegler SI, Schwaiger M, Krause BJ
Mol Imag Biol 2011;13(5):1011-1